DK2766014T3 - Fremgangsmåder til behandling af pædiatriske patienter under anvendelse af dexmedetomidin - Google Patents

Fremgangsmåder til behandling af pædiatriske patienter under anvendelse af dexmedetomidin Download PDF

Info

Publication number
DK2766014T3
DK2766014T3 DK12840033.0T DK12840033T DK2766014T3 DK 2766014 T3 DK2766014 T3 DK 2766014T3 DK 12840033 T DK12840033 T DK 12840033T DK 2766014 T3 DK2766014 T3 DK 2766014T3
Authority
DK
Denmark
Prior art keywords
dexmedetomidine
dose
hours
administered
weeks
Prior art date
Application number
DK12840033.0T
Other languages
English (en)
Inventor
De Rocha Marcelo Garcia
Wayne Wisemandle
Dennis J Stalker
Edward Koo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2766014(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc filed Critical Hospira Inc
Application granted granted Critical
Publication of DK2766014T3 publication Critical patent/DK2766014T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (11)

1
1. Dexmedetomidin til anvendelse til sedation eller analgesi hos en pædiatrisk patient med behov herfor, 5 hvor den pædriatiske patient har en gestationsalder på fra 20 uger til 44 uger, hvor indgivelsen af dexmedetomidin omfatter en første initialdosis indgivet i løbet af et tidsrum på fra 10 til 20 minutter før en anden vedligeholdelsesdosis, hvor initialdosen er 0,4 pg/kg eller mindre, hvor dexmedetomidin i den anden vedligeholdelsesdosis indgives som en kon-10 tinuerlig intravenøs dosis til den pædiatriske patient i en koncentration på mel lem 0,005 pg/kg/t til 0,25 pg/kg/t, og hvor dexmedetomidin indgives som en kontinuerlig infusion i løbet af et tidsrum på mindre end 36 timer.
2. Dexmedetomidin til anvendelse ifølge krav 1, hvor dexmedetomidin indgives som en kontinuerlig dosis i løbet af et tidsrum på mellem 6 og 24 timer.
3. Dexmedetomidin til anvendelse ifølge krav 1, hvor den pædiatriske patient intuberes før, under eller efter indgivelse af dexmedetomidin. 20
4. Dexmedetomidin til anvendelse ifølge krav 1, hvor den pædiatriske patient er kritisk syg.
5. Dexmedetomidin til anvendelse ifølge krav 1, hvor dexmedetomidin indgives 25 før kirurgi.
6. Dexmedetomidin til anvendelse ifølge krav 1, hvor dexmedetomidin indgives efter kirurgi.
7. Dexmedetomidin til anvendelse ifølge krav 6, hvor dexmedetomidin indgives efter kardiopulmonal bypass.
8. Dexmedetomidin til anvendelse ifølge krav 1, hvor indgivelsen af dexmedetomidin reducerer et behov for redningsmedicin. 35 2
9. Dexmedetomidin til anvendelse ifølge krav 8, hvor redningsmedicinen er et sedativ; eller hvor redningsmedicinen er et analgetikum.
10. Dexmedetomidin til anvendelse ifølge krav 1, hvor dexmedetomidin indgi- 5 ves i en mængde, der er virksom til at reducere en forekomst af neurologisk skade.
11. Dexmedetomidin til anvendelse ifølge krav 1, hvor den pædiatriske patient har en gestationsalder på mellem 28 uger og 44 uger.
DK12840033.0T 2011-10-14 2012-09-27 Fremgangsmåder til behandling af pædiatriske patienter under anvendelse af dexmedetomidin DK2766014T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547626P 2011-10-14 2011-10-14
US13/343,693 US20130096170A1 (en) 2011-10-14 2012-01-04 Methods of treating pediatric patients using dexmedetomidine
US13/471,403 US8324260B1 (en) 2011-10-14 2012-05-14 Methods of treating pediatric patients using dexmedetomidine
PCT/US2012/057652 WO2013055528A1 (en) 2011-10-14 2012-09-27 Methods of treating pediatric patients using dexmedetomidine

Publications (1)

Publication Number Publication Date
DK2766014T3 true DK2766014T3 (da) 2018-09-24

Family

ID=47226666

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12840033.0T DK2766014T3 (da) 2011-10-14 2012-09-27 Fremgangsmåder til behandling af pædiatriske patienter under anvendelse af dexmedetomidin

Country Status (23)

Country Link
US (8) US20130096170A1 (da)
EP (2) EP2766014B1 (da)
JP (5) JP6270727B2 (da)
KR (3) KR20200019791A (da)
CN (2) CN103957906A (da)
AU (3) AU2012321246C1 (da)
BR (1) BR112014008983A2 (da)
CA (2) CA2851780C (da)
CY (1) CY1121041T1 (da)
DK (1) DK2766014T3 (da)
ES (1) ES2685814T3 (da)
HK (1) HK1200333A1 (da)
HR (1) HRP20181378T1 (da)
HU (1) HUE039671T2 (da)
IL (2) IL232070A0 (da)
IN (1) IN2014KN00996A (da)
LT (1) LT2766014T (da)
MX (1) MX362626B (da)
PL (1) PL2766014T3 (da)
PT (1) PT2766014T (da)
RS (1) RS57660B1 (da)
SI (1) SI2766014T1 (da)
WO (1) WO2013055528A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
KR101891186B1 (ko) * 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
RU2648449C2 (ru) * 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
TWI645866B (zh) 2013-10-07 2019-01-01 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
US11017330B2 (en) * 2014-05-20 2021-05-25 Elasticsearch B.V. Method and system for analysing data
EP3182893B1 (en) 2014-08-18 2024-02-07 Electronic Pain Assessment Technologies (EPAT) Pty Ltd A pain assessment system
CN104784174A (zh) * 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
JP2019534288A (ja) * 2016-10-31 2019-11-28 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
CN106539778A (zh) * 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
MX2019007923A (es) 2016-12-31 2019-09-10 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
US11783046B2 (en) 2017-04-26 2023-10-10 Elasticsearch B.V. Anomaly and causation detection in computing environments
US11621969B2 (en) 2017-04-26 2023-04-04 Elasticsearch B.V. Clustering and outlier detection in anomaly and causation detection for computing environments
CN108042533B (zh) * 2017-12-25 2020-11-13 苏州格兰科医药科技有限公司 右美托米定在制备用于预防和/或抑制创伤性脑损伤后的神经元死亡的药物组合物中的用途
EP3813828A4 (en) * 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
US10792246B2 (en) 2018-06-27 2020-10-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
JP2022500407A (ja) * 2018-09-12 2022-01-04 ハフ イアー インスティテュート 人工内耳手術に伴う難聴の治療方法
US20220054455A1 (en) * 2018-09-13 2022-02-24 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
WO2020123680A1 (en) * 2018-12-13 2020-06-18 Dignity Health System and method for detection and monitoring of over sedation to prevent harm to patients
US10817669B2 (en) 2019-01-14 2020-10-27 International Business Machines Corporation Automatic classification of adverse event text fragments
CN109793709A (zh) * 2019-02-22 2019-05-24 青岛农业大学 一种斑海豹用复方注射剂及其制备方法
US11000488B2 (en) * 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021211507A1 (en) * 2020-04-17 2021-10-21 Bioventures, Llc Methods and systems for predicting the effect of inhaled and infused anesthetics
KR20230094816A (ko) 2021-12-21 2023-06-28 충남대학교산학협력단 감염 환자에서 반코마이신 최적 용량을 결정하는 방법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
JPS6058890A (ja) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd 感熱記録紙用填剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
WO1996004904A1 (fr) 1994-08-08 1996-02-22 Debiopharm S.A. Preparation pharmaceutiquement stable d'oxaliplatine
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6716867B1 (en) * 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
US20080308444A1 (en) 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8100890B2 (en) * 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
US7896843B2 (en) * 2008-10-15 2011-03-01 Bioquiddity, Inc. Special purpose fluid dispenser
WO2010050211A1 (ja) 2008-10-30 2010-05-06 国立大学法人 岡山大学 局所麻酔用組成物
BRPI1010567A2 (pt) 2009-05-15 2016-03-15 Recro Pharma Inc composições sublinguais de dexmedetomidina e métodos de uso e aparelho que os emprega
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
US20110152271A1 (en) 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (fr) 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
JP2014528474A (ja) 2014-10-27
KR20190029775A (ko) 2019-03-20
US20190269657A1 (en) 2019-09-05
US20160067220A1 (en) 2016-03-10
AU2019203564A1 (en) 2019-06-13
BR112014008983A2 (pt) 2017-05-02
HUE039671T2 (hu) 2019-01-28
AU2012321246B2 (en) 2017-05-04
JP2022008828A (ja) 2022-01-14
LT2766014T (lt) 2018-08-27
JP6270727B2 (ja) 2018-01-31
US20140005243A1 (en) 2014-01-02
AU2012321246A1 (en) 2014-05-01
EP2766014A4 (en) 2015-06-24
EP2766014A1 (en) 2014-08-20
IN2014KN00996A (da) 2015-09-04
MX2014004548A (es) 2015-02-12
CY1121041T1 (el) 2019-12-11
PT2766014T (pt) 2018-10-11
EP2766014B1 (en) 2018-07-18
SI2766014T1 (sl) 2018-11-30
IL232070A0 (en) 2014-05-28
JP2020073529A (ja) 2020-05-14
US20130096172A1 (en) 2013-04-18
IL249991A0 (en) 2017-03-30
AU2017206211B2 (en) 2019-02-28
JP6640164B2 (ja) 2020-02-05
AU2017206211A1 (en) 2017-08-03
CN103957906A (zh) 2014-07-30
KR20140094539A (ko) 2014-07-30
MX362626B (es) 2019-01-28
HRP20181378T1 (hr) 2018-10-19
HK1200333A1 (en) 2015-08-07
CA2851780A1 (en) 2013-04-18
AU2012321246C1 (en) 2017-11-02
WO2013055528A1 (en) 2013-04-18
US8324260B1 (en) 2012-12-04
KR20200019791A (ko) 2020-02-24
PL2766014T3 (pl) 2019-02-28
US20130096171A1 (en) 2013-04-18
EP3446691A1 (en) 2019-02-27
US20210137891A1 (en) 2021-05-13
ES2685814T3 (es) 2018-10-11
US8507542B2 (en) 2013-08-13
US9314449B2 (en) 2016-04-19
US20130096170A1 (en) 2013-04-18
CA2851780C (en) 2017-11-28
CA2978258A1 (en) 2013-04-18
RS57660B1 (sr) 2018-11-30
JP2018027971A (ja) 2018-02-22
JP2023179764A (ja) 2023-12-19
CN109700806A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
DK2766014T3 (da) Fremgangsmåder til behandling af pædiatriske patienter under anvendelse af dexmedetomidin
Guglielminotti et al. Effects of premedication on dose requirements for propofol: comparison of clonidine and hydroxyzine.
Wang et al. Negative words on surgical wards result in therapeutic failure of patient-controlled analgesia and further release of cortisol after abdominal surgeries
Zhao et al. Propofol and sevoflurane combined with remifentanil on the pain index, inflammatory factors and postoperative cognitive function of spine fracture patients
Yokoyama et al. Low-dose sirolimus for a patient with blue rubber bleb nevus syndrome
KR102606504B1 (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
Jiang et al. Low body weight predicted bradycardia and desaturation in retinopathy of prematurity surgeries: a retrospective cohort study
Lascola et al. Anesthetic Management of Foals
Eskandr et al. Dexmedetomidine as a part of general anaesthesia for caesarean delivery in patients with pre-eclampsia Efficacy and foetal outcome: a randomised double-blinded trial
Carlyle et al. 12 Chronic Disease of Childhood
EP3114135A2 (en) Treatment of neonatal brain injury with hb-egf
CN113995767A (zh) 烟酰胺核糖在制备肺纤维化治疗药物中的应用
Reshma Effect of Preanaesthetic Single Infusion of Dexmedetomidine on Isoflurane Consumption in Surgical Patients Under General Anaesthesia